Gene signature to predict homologous recombination (hr) deficient cancer: U.S. Patent Application 14/772,549[P].

The U.S. Patent Application Gene signature to predict homologous recombination (hr) deficient cancer: U.S. Patent Application 14/772,549[P]. Authors: Lin C J, Peng G, Lin S Y, et al.
Publication number: WO2014138101 A1

Abstract

Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.